NGAL, as one of the more reliable early biomarkers, has been widely studied not only in terms of contrast kidney damage but also in other conditions such as critically ill patients in intensive care units or AKI after aortocoronary bypass surgery, with demonstrated good diagnostic power in individual studies [31,32,33] and some meta-analyses [34,35,36]. Here, LCN2 is linked to acute kidney injury.